Bioventus Inc(BVS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:10 PM ET (Korea 9/12 05:10)
Full metrics table
| Index | RUT | P/E | 16.74 | EPS (ttm) | 0.78 | Insider Own | 31.08% | Shs Outstand | 68.2M | Perf Week | -9.61% |
| Market Cap | 1.09B | Forward P/E | 14.1 | EPS next Y | 18.44% | Insider Trans | -0.05% | Shs Float | 47.1M | Perf Month | -6.72% |
| Enterprise Value | 1.37B | PEG | 0.88 | EPS next Q | 0.16 | Inst Own | 60.12% | Short Float | 5.48% | Perf Quarter | 49.54% |
| Income | 0.05B | P/S | 1.88 | EPS this Y | 14.28% | Inst Trans | 4.85% | Short Ratio | 3.65 | Perf Half Y | 50.93% |
| Sales | 0.58B | P/B | 3.88 | EPS next 5Y | 16.02% | ROA | 7.89% | Short Interest | 2.58M | Perf YTD | 74.46% |
| Book/sh | 3.35 | P/C | 37.05 | EPS past 3/5Y | - 33.74% | ROE | 27.96% | 52W High | -18.33% ($15.89) | Perf Year | 78.3% |
| Cash/sh | 0.35 | P/FCF | 11.66 | Sales past 3/5Y | 3.52% 12.08% | ROIC | 11.61% | 52W Low | 107.51% ($6.26) | Perf 3Y | 306.9% |
| Dividend Est. | - | EV/EBITDA | 12.89 | EPS Y/Y TTM | 19765.85% | Gross Margin | 67.82% | Volatility(W/M) | 3.62% 3.6% | Perf 5Y | -11.58% |
| Dividend TTM | - | EV/Sales | 2.36 | Sales Y/Y TTM | 3.14% | Oper. Margin | 10.56% | ATR (14) | 0.55 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.17 | EPS Q/Q | 333.92% | Profit Margin | 9.36% | RSI (14) | 41.19 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.69 | Sales Q/Q | 3.76% | SMA20 | -7% ($13.96) | Beta | 0.65 | Target Price | $17.6 |
| Payout | - | Debt/Eq | 1.16 | Earnings | 2026/8/5 | SMA50 | -1.45% ($13.17) | Rel Volume | 0.6 | Prev Close | $13.06 |
| Employees | 930 | LT Debt/Eq | 1.05 | EPS/Sales Surpr. | 1.71% -1.44% | SMA200 | 31.98% ($9.83) | Avg Volume(3M) | 0.71M | Price | $12.98 |
| IPO | 2021/2/11 | Option/Short | Yes/Yes | Trades | 6409 | Volume | 421,804 | Change | -0.61% |
Company
BVS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
Bioventus (BVS) is a U.S. medical device company specializing in orthobiologics. Through its portfolio of active healing therapies and surgical products designed to relieve pain and support bone healing, the company helps patients achieve faster, safer recoveries, delivering clinically proven solutions in orthopedics and rehabilitation on a global scale.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
BVS makes money exceptionally well
10.56% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +14.3% this year.
Tap to view numbers
The stock looks undervalued
Trading at 16.7 times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +306.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 60.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
FDLS 0.01%
XHE 0.01%
QQQS 0.00%
SVAL 0.00%
SQLV 0.00%It ranks #4 in the industry
Based on market cap of $1B.
BVS $1B PER 16.7
ABT $176B PER 33.0
MDT $116B PER 22.4
SYK $106B PER 28.6
FAQ
What kind of company is BVS?
BVS belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of BVS?
The market cap of BVS is approximately $1.1B, ranking 2,582 within its sector.
What is the P/E ratio of BVS?
BVS has a P/E ratio of approximately 16.7x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BVS?
BVS has recorded a 52-week high of $15.89 and a low of $6.26.
